Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer

Genomics, Proteomics and Bioinformatics

Volumn 12, Issue 5, 2014, Pages 198-209

  Rose, Maimon C ^a   Kostyanovskaya, Elina ^a   Huang, R Stephanie ^b  

^a Department of Obstetrics and Gynecology   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Biomarker; Cisplatin; Copper transport; Glutathione S transferase; Non small cell lung cancer; Nucleotide excision repair

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M; GLUTATHIONE TRANSFERASE P1; MENKES PROTEIN; PORTEIN CTR1; PROTEIN; PROTEIN CTR2; UNCLASSIFIED DRUG; WILSON DISEASE PROTEIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ATP7A GENE; ATP7B GENE; CHEMOSENSITIVITY; CTR1 GENE; CTR2 GENE; DNA ADDUCT; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; EXCISION REPAIR; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GERM LINE; HUMAN; NON SMALL CELL LUNG CANCER; NONHUMAN; PHARMACOGENOMICS; REVIEW; XP GENE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; PHARMACOGENETICS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS;

EID: 84922547035     PISSN: 16720229     EISSN: 22103244     Source Type: Journal    
DOI: 10.1016/j.gpb.2014.10.003     Document Type: Review

References (105)

1. WHO cancer factsheet. 2014 [accessed 25.05.14]. http://www.who.int/mediacentre/factsheets/fs297/en/.
2. American Cancer Society Cancer facts and figures 2014 2014, American Cancer Society, Atlanta.
3. Yin J.Y., Huang Q., Zhao Y.C., Zhou H.H., Liu Z.Q. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One 2012, 7:e38150.
4. National Cancer Institute. Non-small cell lung cancer treatment. 2014 [accessed 25.05.14]. http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/page10.
5. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
6. Kuo M.T., Chen H.H., Song I.S., Savaraj N., Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007, 26:71-83.
7. van der Straaten T., Mullenders L., Guchelaar H.J. Pharmacogenetics of cancer and DNA repair enzymes. DNA repair and human health [internet] 2011, 597-612. Intech, Richardson. S. Vengrova (Ed.).
8. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23.
9. Huang J.C., Zamble D.B., Reardon J.T., Lippard S.J., Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A 1994, 91:10394-10398.
10. Fichtinger-Schepman A.M., van der Veer J.L., den Hartog J.H., Lohman P.H., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(ii) with DNA - formation, identification, and quantitation. Biochemistry 1985, 24:707-713.
11. Zamble D.B., Mu D., Reardon J.T., Sancar A., Lippard S.J. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996, 35:10004-10013.
12. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat Res Fundam Mol Mech Mutagen 2001, 478:23-43.
13. Rosell R., Lord R.V., Taron M., Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002, 38:217-227.
14. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62:4899-4902.
15. Rosell R., Taron M., Barnadas A., Scagliotti G., Sarries C., Roig B. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003, 10:297-305.
16. De Silva I.U., McHugh P.J., Clingen P.H., Hartley J.A. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002, 30:3848-3856.
17. Dabholkar M., Vionnet J., Bostickbruton F., Yu J.J., Reed E. Messenger-RNA levels of XPAC and ERCC1 in ovarian-cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994, 94:703-708.
18. Takenaka T., Yoshino I., Kouso H., Ohba T., Yohena T., Osoegawa A., et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 2007, 121:895-900.
19. Wang L., Wei J., Qian X., Yin H., Zhao Y., Yu L., et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008, 8:97.
20. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
21. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
22. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
23. Fan W., Zhang H.L., Wu X.M. Enhancement effect of nucleotide excision repair gene xeroderma pigmentosum group A antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin. Chin J Cancer 2005, 24:403-407.
24. Zhang Q., Wu J.X., Wei Y.P., Hao J.Q., Huang S.Y., Dong L. Effect of XPA expression on the chemotherapy sensitivity of A549/DDP cells. Chin J Cell Mol Immunol 2012, 28:1182-1184.
25. Liu Y., Bernauer A.M., Yingling C.M., Belinsky S.A. HIF1 alpha regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis 2012, 33:1187-1192.
26. Chen H.H., Yan J.J., Chen W.C., Kuo M.T., Lai Y.H., Lai W.W., et al. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 2012, 75:228-234.
27. Song I.S., Savaraj N., Siddik Z.H., Liu P.M., Wei Y.J., Wu C.J., et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004, 3:1543-1549.
28. Lin X.J., Okuda T., Holzer A., Howell S.B. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 2002, 62:1154-1159.
29. Ishida S., Lee J., Thiele D.J., Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad of Sci U S A 2002, 99:14298-14302.
30. Li Z.H., Qiu M.Z., Zeng Z.L., Luo H.Y., Wu W.J., Wang F., et al. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). J Transl Med 2012, 10:21.
31. Song L., Li Y., Li W., Wu S., Li Z. MiR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem 2014, 115:1234-1242.
32. Nakayama K., Kanzaki A., Terada K., Mutoh M., Ogawa K., Sugiyama T., et al. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res 2004, 10:2804-2811.
33. Konkimalla V.B., Kaina B., Efferth T. Role of transporter genes in cisplatin resistance. In Vivo 2008, 22:279-283.
34. Inoue Y., Matsumoto H., Yamada S., Kawai K., Suemizu H., Gika M., et al. ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer. Oncol Lett 2010, 1:279-282.
35. Nakagawa T., Inoue Y., Kodama H., Yamazaki H., Kawai K., Suemizu H., et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol Rep 2008, 20:265-270.
36. Nakagawa K., Yokota J., Wada M., Sasaki Y., Fujiwara Y., Sakai M., et al. Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn J Cancer Res 1988, 79:301-304.
37. Arai T., Yasuda Y., Takaya T., Yoshimi N., Ito H., Fujiwara H. Correlation between the immunohistochemical and mRNA expression of glutathione S-transferase-pi and cisplatin plus etoposide chemotherapy response in patients with untreated primary non-small cell lung cancer. Int J Oncol 1997, 11:127-131.
38. Arai T., Yasuda Y., Takaya T., Hayakawa K., Toshima S., Shibuya C., et al. Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer. Cancer Detect Prev 2000, 24:252-257.
39. Hida T., Ariyoshi Y., Kuwabara M., Sugiura T., Takahashi T., Hosoda K., et al. Glutathione S-transferase pi levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity. Jpn J Clin Oncol 1993, 23:14-19.
40. Hirano T., Kato H., Maeda M., Gong Y.B., Shou Y.N., Nakamura M., et al. Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker. Int J Cancer 2005, 117:460-468.
41. Allen T.C., Granville L.A., Cagle P.T., Haque A., Zander D.S., Barrios R. Expression of glutathione S-transferase pi and glutathione synthase correlates with survival in early stage non-small cell carcinomas of the lung. Hum Pathol 2007, 38:220-227.
42. Rosell R., Scagliotti G., Danenberg K.D., Lord R.V., Bepler G., Novello S., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003, 22:3548-3553.
43. Townsend A.J., Tu C.P., Cowan K.H. Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: effect on cellular sensitivity to cytotoxic agents. Mol Pharmacol 1992, 41:230-236.
44. Waxman D.J., Sundseth S.S., Srivastava P.K., Lapenson D.P. Gene-specific oligonucleotide probes for alpha, mu, pi, and microsomal rat glutathione S-transferases: analysis of liver transferase expression and its modulation by hepatic enzyme inducers and platinum anticancer drugs. Cancer Res 1992, 52:5797-5802.
45. Wang C.H., Wu H.T., Cheng H.M., Yen T.J., Lu I.H., Chang H.C., et al. Inhibition of glutathione S-transferase M1 by new gabosine analogues is essential for overcoming cisplatin resistance in lung cancer cells. J Med Chem 2011, 54:8574-8581.
46. Wachters F.M., Wong L.S., Timens W., Kampinga H.H., Groen H.J. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005, 50:211-219.
47. Booton R., Ward T., Ashcroft L., Morris J., Heighway J., Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007, 2:902-906.
48. Glaysher S., Yiannakis D., Gabriel F.G., Johnson P., Polak M.E., Knight L.A., et al. Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer 2009, 9:1-17.
49. Friboulet L., Olaussen K.A., Pignon J.P., Shepard F.A., Tsao M.S., Graziano S., et al. ERCC1 isoform expression and DNA repair in non-small cell lung cancer. N Engl J Med 2013, 368:1101-1110.
50. Schneider J.G., Farhadfar N., Sivapiragasam A., Geller M., Islam S., Selbs E. Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer. Oncologist 2014, 19:459-465.
51. Stewart D.J. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010, 75:173-234.
52. Wei S.Z., Zhan P., Shi M.Q., Shi Y., Qian Q., Yu L.K., et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 2011, 28:315-321.
53. Wei H.B., Hu J., Shang L.H., Zhang Y.Y., Lu F.F., Wei M., et al. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2012, 125:2902-2907.
54. Yu D., Shi J., Sun T., Du X., Liu L., Zhang X., et al. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumor Biol 2012, 33:877-884.
55. Qin Q., Zhang C., Yang X., Zhu H., Yang B., Cai J., et al. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies. PLoS One 2013, 8:e79864.
56. Xu X., Duan L., Zhou B., Ma R., Zhou H., Liu Z. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin Exp Pharmacol Physiol 2012, 39:786-792.
57. Wu X., Lu C., Ye Y., Chang J., Yang H., Lin J., et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 2008, 18:955-965.
58. Sun N., Sun X., Chen B., Cheng H., Feng J., Cheng L., et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2010, 65:437-446.
59. Zhou F., Yu Z., Jiang T., Lv H., Yao R., Liang J. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med Wkly 2011, 141:w13275.
60. Booton R., Ward T., Heighway J., Ashcroft L., Morris J., Thatcher N. Glutathione S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol 2006, 1:679-683.
61. Lu C., Spitz M.R., Zhao H., Dong Q., Truong M., Chang J.Y., et al. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 2006, 106:441-447.
62. Yang Y., Xian L. The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis. Tumor Biol 2014, 35:6791-6799.
63. Moyer A.M., Sun Z., Batzler A.J., Li L., Schaid D.J., Yang P., et al. Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 2010, 19:811-821.
64. Wu X.M., Fan W., Xu S.W., Zhou Y.K. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosum group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res 2003, 9:5874-5879.
65. Rosenberg E., Taher M.M., Kuemmerle N.B., Farnsworth J., Valerie K. A truncated human xeroderma pigmentosum complementation group a protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Cancer Res 2001, 61:764-770.
66. Gately D.P., Howell S.B. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993, 67:1171-1176.
67. Kim E.S., Lee J.J., He G., Chow C.W., Fujimoto J., Kalhor N., et al. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 2012, 30:3345-3352.
68. Zhou B., Gitschier J. HCTR1: a human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci U S A 1997, 94:7481-7486.
69. Safaei R., Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005, 53:13-23.
70. Holzer A.K., Manorek G.H., Howell S.B. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006, 70:1390-1394.
71. Zisowsky J., Koegel S., Leyers S., Devarakonda K., Kassack M.U., Osmak M., et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 2007, 73:298-307.
72. Larson C.A., Blair B.G., Safaei R., Howell S.B. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 2009, 75:324-330.
73. Larson C.A., Adams P.L., Jandial D.D., Blair B.G., Safaei R., Howell S.B. The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochem Pharmacol 2010, 80:448-454.
74. Kalayda G.V., Wagner C.H., Jaehde U. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. J Inorg Biochem 2012, 116:1-10.
75. Ishida S., McCormick F., Smith-McCune K., Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17:574-583.
76. Fu S., Naing A., Fu C., Kuo M.T., Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther 2012, 11:1221-1225.
77. Ivy K.D., Kaplan J.H. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol 2013, 83:1237-1246.
78. Hall M.D., Okabe M., Shen D.W., Liang X.J., Gottesman M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008, 48:495-535.
79. Wee N.K., Weinstein D.C., Fraser S.T., Assinder S.J. The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease. Int J Biochem Cell Biol 2013, 45:960-963.
80. Blair B.G., Larson C.A., Safaei R., Howell S.B. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res 2009, 15:4312-4321.
81. Huang C.P., Fofana M., Chan J., Chang C.J., Howell S.B. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics 2014, 6:654-661.
82. Ohrvik H., Thiele D.J. The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy. J Trace Elem Med Biol 2014, 10.1016/j.jtemb.2014.03.006.
83. Vulpe C., Levinson B., Whitney S., Packman S., Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet 1993, 3:7-13.
84. Bull P.C., Thomas G.R., Rommens J.M., Forbes J.R., Cox D.W. The Wilson disease gene is a putative copper transporting p-type ATPase similar to the Menkes gene. Nat Genet 1993, 5:327-337.
85. Samimi G., Varki N.M., Wilczynski S., Safaei R., Alberts D.S., Howell S.B. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 2003, 9:5853-5859.
86. Samimi G., Safaei R., Katano K., Holzer A.K., Rochdi M., Tomioka M., et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 2004, 10:4661-4669.
87. Komatsu M., Sumizawa T., Mutoh M., Chen Z.S., Terada K., Furukawa T., et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000, 60:1312-1316.
88. Hildebrandt M.A., Gu J., Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 2009, 5:745-755.
89. Fukushima-Uesaka H., Saito Y., Maekawa K., Kurose K., Sugiyama E., Katori N., et al. Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab Pharmacokinet 2009, 24:565-574.
90. Anttila S., Hirvonen A., Vainio H., Husgafvel-Pursiainen K., Hayes J.D., Ketterer B. Immunohistochemical localization of glutathione S-transferases in human lung. Cancer Res 1993, 53:5643-5648.
91. Terrier P., Townsend A.J., Coindre J.M., Triche T.J., Cowan K.H. An immunohistochemical study of pi-class glutathione S-transferase expression in normal human tissue. Am J Pathol 1990, 137:845-853.
92. Peklak-Scott C., Smitherman P.K., Townsend A.J., Morrow C.S. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008, 7:3247-3255.
93. Tew K.D. Glutathione-associated enzymes in anticancer drug-resistance. Cancer Res 1994, 54:4313-4320.
94. Watson M.A., Stewart R.K., Smith G.B., Massey T.E., Bell D.A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998, 19:275-280.
95. Allan J.M., Wild C.P., Rollinson S., Willett E.V., Moorman A.V., Dovey G.J., et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A 2001, 98:11592-11597.
96. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995, 30:445-600.
97. Saburi Y., Nakagawa M., Ono M., Sakai M., Muramatsu M., Kohno K., et al. Increased expression of glutathione S-transferase gene in cis-diamminedichloro-platinum(ii)-resistant variants of a Chinese hamster ovary cell line. Cancer Res 1989, 49:7020-7025.
98. Watson M.B., Lind M.J., Smith L., Drew P.J., Cawkwell L. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model. Acta Oncol 2007, 46:651-658.
99. Smith L., Welham K.J., Watson M.B., Drew P.J., Lind M.J., Cawkwell L. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res 2007, 16:497-506.
100. Wheeler H.E., Gamazon E.R., Stark A.L., O'Donnel P.H., Gorsic L.K., et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 2013, 13:35-43.
101. Hayes J.D., Strange R.C. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000, 61:154-166.
102. Lin H.J., Han C.Y., Bernstein D.A., Hsiao W., Lin B.K., Hardy S. Ethnic distribution of the glutathione transferase mu-1-1 (GSTM1) null genotype in 1473 individuals and application to bladder-cancer susceptibility. Carcinogenesis 1994, 15:1077-1081.
103. Horgan A.M., Yang B., Azad A.K., Amir E., John T., Cescon D.W., et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol 2011, 6:296-304.
104. Sweeney C., Nazar-Stewart V., Stapleton P.L., Eaton D.L., Vaughan T.L. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003, 12:527-533.
105. Gonlugur U., Pinarbasi H., Gonlugur T.E., Silig Y. The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome. Cancer Invest 2006, 24:497-501.